The synthesis and evaluation of cyclic ureas as HIV protease inhibitors:: Modifications of the P1/P1′ residues

被引：29
|
作者：
Patel, M
Bacheler, LT
Rayner, MM
Cordova, BC
Klabe, RM
Erickson-Viitanen, S
Seitz, SP
机构：
[1] Dupont Merck Pharmaceut Co, Expt Stn, Dept Chem & Phys Sci, Wilmington, DE 19880 USA
[2] Dupont Merck Pharmaceut Co, Expt Stn, Dept Virol, Wilmington, DE 19880 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1998年 / 8卷 / 07期
关键词：
D O I：
10.1016/S0960-894X(98)00119-X
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity. Compounds 8b, 10 (3- and 4-pyridylmethyl analogs) and 6b (4-methoxy analog) showed significant improvement in antiviral activity relative to lead compounds DMP323 and DMP 450. (C) 1998 The DuPont Merck Pharmaceutical Company. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：823 / 828
页数：6
相关论文
共 50 条
  • [11] P1/P1′ modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays
    Alterman, M
    Sjöbom, H
    Säfsten, P
    Markgren, PO
    Danielson, UH
    Hämäläinen, M
    Löfås, S
    Hultén, J
    Classon, B
    Samuelsson, B
    Hallberg, A
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) : 203 - 212
  • [12] Design and fast synthesis of C-terminal duplicated potent C2-symmetric P1/P1′-modified HIV-1 protease inhibitors
    Alterman, M
    Andersson, HO
    Garg, N
    Ahlsén, G
    Lövgren, S
    Classon, B
    Danielson, UH
    Kvarnström, I
    Vrang, L
    Unge, T
    Samuelsson, B
    Hallberg, A
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (19) : 3835 - 3844
  • [13] Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors
    Bally, F
    Martinez, R
    Peters, S
    Sudre, P
    Telenti, A
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (13) : 1209 - 1213
  • [14] P1 AND P1' MODIFIED PHOSPHINIC DIPEPTIDE ANALOGUE INHIBITORS OF METALLOAMINOPEPTIDASES
    Talma, M.
    Weglarz-Tomczak, E.
    Staszewska, K.
    Mucha, A.
    JOURNAL OF PEPTIDE SCIENCE, 2016, 22 : S184 - S184
  • [15] Design, synthesis and evaluation of diaroyl cyclic ureas as Factor Xa inhibitors utilizing a neutral P1 residue as arginine surrogate.
    Cui, J
    Alkassoum, S
    Zhou, YS
    Wanna, L
    Crich, D
    Johnson, ME
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U1180 - U1180
  • [16] Synthesis of potent C2-symmetric, diol-based HIV-1 protease inhibitors.: Investigation of thioalkyl and thioaryl P1/P1′ substituents
    Mühlman, A
    Classon, B
    Hallberg, A
    Samuelsson, B
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (21) : 3402 - 3406
  • [17] New, potent P1/P2-morpholinone-based HIV-protease inhibitors
    Kazmierski, Wieslaw M.
    Furfine, Eric
    Spaltenstein, Andrew
    Wright, Lois L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (19) : 5226 - 5230
  • [18] Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1′ ligand
    Dou, Yue
    Zhu, Mei
    Dong, Biao
    Wang, Ju-Xian
    Zhang, Guo-Ning
    Zhang, Fan
    Wang, Yu-Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (07)
  • [19] PLASMIN SPECIFIC INHIBITORS: OPTIMIZATION OF THE P2 AND P1' RESIDUES
    Iwasa, N.
    Masuda, T.
    Kuno, M.
    Hidaka, K.
    Hojo, K.
    Gohda, K.
    Teno, N.
    Wanaka, K.
    Tsuda, Y.
    JOURNAL OF PEPTIDE SCIENCE, 2016, 22 : S146 - S146
  • [20] One-pot carbanionic synthesis of P1,P2-diglycosyl, P1,P1,P2-triglycosyl, and P1,P1,P2,P2-tetraribosyl methylenediphosphonates
    Grison, Claude
    Chibli, Hicham
    Barthes, Nicolas
    Coutrot, Philippe
    JOURNAL OF ORGANIC CHEMISTRY, 2006, 71 (21): : 7978 - 7988
12345